Larimar Therapeutics names John B. Harlow Jr. president and COO
The board's appointment, effective September 29, 2026, comes with a $560,000 base salary, a $35,000 signing bonus, and inducement equity grants.
SEC filing
Latest
28 stories
Yesterday
Tuesday, September 29
Friday, September 25
ADARx prices IPO at $17 per share, AbbVie to buy stake
ADARx Pharmaceuticals sold 26.25 million shares in its Nasdaq debut and will use proceeds to fund late-stage siRNA programs including a Phase 3 hereditary angioedema trial.
SEC filing
Thursday, September 24
Novartis updates Scemblix label; registers PV real-world study and CAD trial
Wednesday, September 16
Novartis updates Zortress label; advances Fanconi anemia and IgAN trials
Tuesday, September 15
Legend Biotech names Ingrid Zhang CEO, effective September 15, 2026
Zhang, formerly Novartis International's Chief Commercial Officer, succeeds interim CEO Alan Bash, who returns to lead the CARVYKTI business.
SEC filing
Friday, September 11
Novartis registers Phase 3 urticaria, pruritus trials; posts malaria and leishmaniasis data
Thursday, September 10
Whitehawk Therapeutics adds Vijay Iyengar to board of directors
The clinical-stage oncology company named the former Incyte executive as a Class III director effective September 9, 2026.
SEC filing
Tuesday, September 8
Novartis starts Phase 2 trial of Monte Rosa's MRT-6160 in Sjögren's disease
Novartis initiated a Phase 2a/b study of the VAV1-directed molecular glue degrader, triggering a $50 million milestone payment to Monte Rosa under their license agreement.
SEC filing
Friday, September 4
Novartis's pelacarsen fails cardiovascular outcomes trial in Phase 3 study
Lp(a)HORIZON did not reduce cardiovascular events despite lowering Lp(a) levels, Ionis and partner Novartis reported.
SEC filing
Novartis roundup: ITP real-world data completed; three trials registered; Utah study terminated
ADARx Pharmaceuticals files S-1 for Nasdaq IPO under ticker ADRX
The San Diego siRNA drugmaker seeks to list its three clinical-stage and two preclinical programs, backed by a $335 million AbbVie upfront payment.
SEC filing
Thursday, August 27
Novartis-linked melanoma trial posts results; new ITP preference survey and LASIK study active
Friday, August 21
Novartis updates Leqvio label; MS study recruiting, thyroid study not yet recruiting
Tuesday, August 18
Entera Bio names Riccardo Camisasca as chief medical officer
The appointment, effective immediately, comes ahead of the company's planned Phase 3 start for its lead osteoporosis candidate EB613.
SEC filing
Wednesday, August 12
Novartis: TOUR006 Phase 2 results posted in CKD; eltrombopag pediatric PK study also reports out
Monday, August 10
Annexon adds retinal surgeon Mark Blumenkranz to board as Muneer Satter departs
The biopharmaceutical company named Blumenkranz a Class II director on August 10, 2026, while longtime director Satter resigned effective immediately before the appointment.
SEC filing
Thursday, August 6
Novartis registers Phase 2 VEXAS trial for arumakimig; posts MS treatment-pattern study results
Generate Biomedicines reports Q2 2026 results, advances asthma and oncology pipeline
Phase 3 asthma trials expand recruitment and an oncology combination study completes enrollment as cash falls to $457.4 million.
SEC filing
Monte Rosa reports Q2 2026 results as MGD pipeline advances on three fronts
Monte Rosa completed enrollment in its MRT-8102 cardiovascular study, activated two other Phase 2 trials, and said cash on hand should fund operations into 2029.
SEC filing
Friday, July 31
FDA approves supplement 37 for Novartis's Pluvicto
The efficacy supplement for the radioligand therapy Pluvicto was approved with a status date of July 31, 2026.
Drugs@FDA
Novartis: Myfortic label update approved; M.D. Anderson posts endometrial trial results
Thursday, July 30
PTC Therapeutics reports Q2 2026 revenue of $361 million, raises full-year guidance
Sephience sales drove product revenue growth as the company reported net income and advanced its Huntington's disease and Friedreich's ataxia programs.
SEC filing
Tuesday, July 28
Relmada names Bipin Dalmia as Chief Business Officer
The clinical-stage biotech brought on the former Ferring uro-oncology executive to help guide strategy for its bladder cancer therapy NDV-01.
SEC filing
Tuesday, July 21
Novartis posts ASSIST Phase 2 results; two pediatric studies listed
Friday, July 17
Novartis posts pelacarsen Phase 3 apheresis results, updates three drug labels
Thursday, July 16
FDA approves new efficacy supplement for Novartis's Fabhalta
Novartis received priority-review approval for a seventh supplement to Fabhalta's original new drug application, expanding the drug's approved use.
Drugs@FDA